Biologics is fastest growing segment fueling the growth of Antibodies Market
Antibodies Market |
Market Overview:
The global Antibodies Market is
estimated to be valued at US$ 224,083.5
Mn in 2023 and is expected to exhibit a CAGR of 12.9% over the forecast period 2023 to 2030, as highlighted
in a new report published by Coherent Market Insights.
Antibodies are proteins produced
by the immune system that recognize and defend against viruses, bacteria, and
other foreign invaders by binding to specific structures on the outside of the
pathogens called antigens. Monoclonal antibodies are artificially produced in
laboratories and can be tailored to bind to certain antigens to treat various
diseases including cancers, autoimmune disorders, and infectious diseases.
Market key trends:
The biologics segment is
projected to be the fastest growing segment in the antibodies market. Biologics
is a newer class of medicines that are made from living cells rather than
chemical compounds. They include recombinant antibodies and genetically
engineered monoclonal antibodies that are used for treating various chronic diseases
and cancers. The growing demand for biologics due to their high specificity and
minimal side effects compared to conventional drugs and vaccines is expected to
drive the growth of this segment in the antibodies market. Furthermore,
continuous research and advancements for developing novel recombinant
monoclonal antibodies targeting specific disease antigens is anticipated to
boost the biologics segment during the forecast period.
Segment Analysis
The global antibodies market can
be segmented based on product type, application, end user and region. Based on
product type, the market is segmented into monoclonal antibodies, polyclonal
antibodies, antibody drug conjugates, and bispecific antibodies. Among these,
the monoclonal antibodies segment dominated the market in 2022 owing to
widespread adoption of monoclonal antibody drugs for treatment of various
diseases like cancer and autoimmune diseases. Monoclonal antibodies provide
high specificity and affinity to target extracellular and cell surface antigens.
Key Takeaways
The Global
Antibodies Market Size is expected to witness high growth, exhibiting
CAGR of 12.9% over the forecast period, due to increasing prevalence of chronic
diseases and rising healthcare expenditure.
Regional analysis
North America dominated the
global antibodies market in 2022 with a share of over 35%, owing to presence of
major market players, availability of advanced healthcare infrastructure, and
rising awareness about antibody drugs. Asia Pacific is expected to exhibit
fastest growth over the forecast period, due to growing healthcare spending,
increasing disposable incomes, and growing incidence of chronic diseases like
cancer.
Key players
Key players operating in the
antibodies market include Novartis AG, F. Hoffmann-La Roche Ltd., Johnson &
Johnson Services, Inc., Takeda Pharmaceutical Company Limited, Amgen Inc.,
Biogen Inc., Bristol-Myers Squibb Company, AbbVie Inc., Sanofi, Eli Lilly and
Co., Iovance Biotherapeutics, Inc., Ultragenyx Pharmaceutical Inc., and Kyowa
Kirin Co., Ltd. Novartis AG and Roche dominate the market with their widely
adopted monoclonal antibody drugs like Avastin, Herceptin, Rituxan, Kadcyla
etc.
Get More Insights Here
https://www.newsstatix.com/antibodies-market-size-share-growth-outlook-2023/
Comments
Post a Comment